These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7090334)

  • 1. Complement in CPD-stored blood.
    Schifferli JA; Boralessa H; Howarth HL; Whitwam JG; Rees AJ
    Vox Sang; 1982; 42(4):198-202. PubMed ID: 7090334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of biochemical changes occurring during storage of red cells. Comparative studies with CPD and CPDA-1 anticoagulant-preservative solutions.
    Moroff G; Dende D
    Transfusion; 1983; 23(6):484-9. PubMed ID: 6649025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of complement components C1q, C3, C4 and C5 to a model immune complex in ELISA.
    Larsson A; Sjöquist J
    J Immunol Methods; 1989 Apr; 119(1):103-9. PubMed ID: 2785142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative pathway of complement by DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (Mergetpa).
    von Zabern I; Nolte R
    Complement; 1986; 3(2):97-104. PubMed ID: 3095022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement in tears from normal humans.
    Yamamoto GK; Allansmith MR
    Am J Ophthalmol; 1979 Oct; 88(4):758-63. PubMed ID: 116549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of the C3 component of complement in sera of hanseniasis patients.
    Kliemann TA; Martinez EL; Irulegui I; de Souza ZW; Cavalcanti ZM
    Hansenol Int; 1983 Jun; 8(1):5-8. PubMed ID: 6432691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement levels and C3 breakdown products in open-heart surgery: association of C3 conversion with the postpericardiotomy syndrome.
    Meri S; Verkkala K; Miettinen A; Valtonen V; Linder E
    Clin Exp Immunol; 1985 Jun; 60(3):597-604. PubMed ID: 3874733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro effects of organic solvents on immunity indicators in serum.
    Stefanovic J; Starsia Z; Murgasová I; Absolonová O
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(1):1-7. PubMed ID: 3571967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of radiographic contrast media on the complement system.
    Hasselbacher P; Hahn J
    J Allergy Clin Immunol; 1980 Sep; 66(3):217-22. PubMed ID: 6251127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the alternative pathway of complement by skin immune deposits.
    Schifferli JA; Steiger G; Polla L; Didierjean L; Saurat JH
    J Invest Dermatol; 1985 Nov; 85(5):407-11. PubMed ID: 3902986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.
    Brandeis WE; Tan C; Wang Y; Good RA; Day NK
    Clin Exp Immunol; 1980 Mar; 39(3):551-61. PubMed ID: 7379328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circulating immune complexes-like material and complement in rheumatoid arthritis and ankylosing spondylitis (author's transl)].
    Rodrigo MJ; Gallart MT; Lience E; Arnal C; Sans J
    Med Clin (Barc); 1981 Apr; 76(8):339-46. PubMed ID: 6789016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural fluid complement, complement conversion, and immune complexes in immunologic and nonimmunologic diseases.
    Hunder GG; McDuffie FC; Huston KA; Elveback LR; Hepper NG
    J Lab Clin Med; 1977 Dec; 90(6):971-80. PubMed ID: 597373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement behavior in infectious mononucleosis: possible mechanisms for the prevention of immune complex injury.
    Charlesworth JA; Endre ZH; Pussell BA; Yasmeen D; Peake PW
    J Infect Dis; 1982 Apr; 145(4):505-13. PubMed ID: 7069231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of a local exhaustion of complement components and of an enzymatic degradation of immunoglobulins in pleural empyema: a possible factor favouring the persistence of local bacterial infections.
    Lew DP; Despont JP; Perrin LH; Aguado MT; Lambert PH; Waldvogel FA
    Clin Exp Immunol; 1980 Dec; 42(3):506-14. PubMed ID: 6908546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.
    Spitzer RE; Stitzel AE; Pauling VL; Davis NC; West CD
    J Exp Med; 1971 Sep; 134(3 Pt 1):656-80. PubMed ID: 15776568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of complement components C3 and factor B in synovial fluids.
    Hunder GG; McDuffie FC; Mullen BJ
    J Lab Clin Med; 1977 Jan; 89(1):160-71. PubMed ID: 830776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use.
    Högman CF; Eriksson L; Gong J; Högman AB; Vikholm K; Debrauwere J; Payrat JM; Stewart M
    Vox Sang; 1993; 65(4):271-8. PubMed ID: 8310679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.
    Mollnes TE; Garred P; Bergseth G
    Clin Exp Immunol; 1988 Sep; 73(3):484-8. PubMed ID: 2463123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum complement levels in patients with rheumatoid arthritis and vasculitis].
    Tomooka K
    Fukuoka Igaku Zasshi; 1989 Oct; 80(10):456-66. PubMed ID: 2613159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.